{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:59:59Z","timestamp":1790236799553,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This retrospective cohort study evaluated the long\u2010term discontinuation (LTD) of osteoporosis treatments in postmenopausal women in France and associated fracture risk and economic burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From the national French health care database (Syst\u00e8me National des Donn\u00e9es de Sant\u00e9), we included postmenopausal women aged \u226560 years initiating oral bisphosphonates, intravenous bisphosphonates, or denosumab between 2012 and 2015 with three or more (bisphosphonates) or two or more (denosumab) years of continuous treatment thereafter. LTD was defined as no treatment for \u226512 months. Within each treatment cohort (intravenous bisphosphonates, oral bisphosphonates, or denosumab), propensity score matching and Cox proportional hazard regression model were used to compare fracture risk in women with versus without LTD, and mean per capita annualized (direct and indirect) costs were assessed between women with and without LTD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 81,263, 19,111, and 28,606 eligible women initiating oral bisphosphonates, intravenous bisphosphonates, and denosumab, respectively, LTD incidence was 55.1%, 68.9%, and 42.5%. LTD of oral bisphosphonates was associated with a 12% increase in fracture risk (hazard ratio [HR] 1.12 [95% confidence interval (CI) 1.06\u20131.19]), and LTD of denosumab was associated with a 92% increase in fracture risk (HR 1.92 [95% CI 1.75\u20132.08]); no significant increase was observed for intravenous bisphosphonates. LTD increased mean per capita annualized costs by \u20ac446.6 for oral bisphosphonates and \u20ac747.2 for denosumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We observed high rates of LTD of osteoporosis treatments among postmenopausal women in France, with LTD of oral bisphosphonates increasing fracture risk by 12% and LTD of denosumab almost doubling fracture risk. These data underscore the need for careful LTD decision\u2010making, especially for denosumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr2.90096","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:48:01Z","timestamp":1788324481000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fracture Risk Associated With Long\u2010Term Discontinuation of Postmenopausal Osteoporosis Treatment: A French Population\u2010Based Study Using National Claims Data (Syst\u00e8me National des Donn\u00e9es de Sant\u00e9)"],"prefix":"10.1002","volume":"8","author":[{"given":"Audrey","family":"Lajoinie","sequence":"first","affiliation":[{"name":"RCTs  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Benmerad","sequence":"additional","affiliation":[{"name":"RCTs  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Laborey","sequence":"additional","affiliation":[{"name":"RCTs  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Samama","sequence":"additional","affiliation":[{"name":"Amgen SAS  Courbevoie France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"D\u00e9sam\u00e9ricq","sequence":"additional","affiliation":[{"name":"Amgen SAS  Courbevoie France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Chelbani","sequence":"additional","affiliation":[{"name":"Amgen SAS  Courbevoie France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Briot","sequence":"additional","affiliation":[{"name":"INSERM U1153, D\u00e9partement de Rhumatologie H\u00f4pital Cochin, APHP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-011-0060-1"},{"key":"e_1_2_8_3_1","unstructured":"World Health Organization Regional Office for Europe.Evidence\u2010informed policy\u2010making: what evidence is there for the prevention and screening of osteoporosis?Accessed June 16 2026.https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/cc050d9f\u201082e7\u20104e6c\u2010af57\u2010354e5e158de\/content"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-019-05002-w"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2016.048"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02207239"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.otsr.2010.04.012"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-00969-8"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rhum.2018.02.005"},{"key":"e_1_2_8_10_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9.Les m\u00e9dicaments de l'ost\u00e9oporose. May 15 2019. Accessed June 16 2026.https:\/\/www.has-sante.fr\/jcms\/c_1751307\/fr\/les-medicaments-de-l-osteoporose"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2017.04.008"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2927"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10629"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2708"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.16.6.1016"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2013.05.013"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3170"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2020.104092"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.433"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01290"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001294"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115890"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-017-0351-2"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3253-4"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3420"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4305"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-022-00771-6"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115150"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115830"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3337"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4335"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.90096","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.90096","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.90096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:21:12Z","timestamp":1790234472000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.90096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/acr2.90096"],"URL":"https:\/\/doi.org\/10.1002\/acr2.90096","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e90096"}}